FDA OKs expanded use of Lilly’s Taltz

The FDA approves Eli Lilly’s (NYSE:LLY) Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis, a type of arthritis affecting the spine and large joints.

The IL-17A inhibitor was approved in the U.S. in March 2016 for plaque psoriasis and in December 2017 for psoriatic arthritis.

https://seekingalpha.com/news/3494506-fda-oks-expanded-use-lillys-taltz